Poster
35
(#35) Real World Assessment of Manic Events among Patients with Bipolar I Disorder Treated with Cariprazine versus Other Atypical Antipsychotics
Psych Congress 2025
Abstract: Introduction: Cariprazine is a dopamine D3 preferring D3/D2 and serotonin 5-HT1A receptor partial agonist atypical antipsychotic(AA) approved for bipolar I disorder (BP-I). Information about cariprazine's real-world effectiveness versus other agents is limited. This study compared BP-I manic events among patients treated with cariprazine, quetiapine, and lurasidone.
Methods: This retrospective observational study used IQVIA PharMetrics® Plus database claims data (September 20142022) and included adults with BP-I and ≥2 claims for cariprazine, quetiapine, or lurasidone. Baseline period was 12 months preceding index (first claim). Follow-up period (≥3 months) spanned index date to earliest of: discontinuation(index AA), exposure to different AA or long-acting injectable antipsychotic, schizophrenia diagnosis, or data end. Manic events per patient-year(PPY) were compared and rate ratios calculated for cariprazine vs comparator AA.
Results: For manic events, cariprazine (n=4,125) versus quetiapine (n=12,177) baseline characteristics were well-balanced; mean age (39.1 vs 39.3 years), sex (64.9% vs 63.2% female); same for cariprazine(n=4,440) versus lurasidone(n=8,134); mean age (38.9 vs 38.8 years), sex (70.3% vs 70.4% female). Cariprazine patients had fewer manic events PPY than quetiapine (RR [95% CI]=0.57[0.44, 0.74], P.001), driven by fewer inpatient(IP)- (RR=0.49[0.30, 0.73], P.001) and outpatient (OP)-defined events (RR=0.57[0.43,0.75], P.001). Cariprazine had fewer manic events PPY than lurasidone (RR=0.71 [0.55, 0.93], P.05), due to fewer IP-defined (RR=0.64[0.45, 0.87], P 01) and OP-defined events (RR=0.71[0.53, 0.96], P.05). ER manic events were not significantly different between AAs.
Conclusions: Cariprazine-treated patients had fewer overall, IP, and OP manic events versus quetiapine or lurasidone, providing real-world evidence of cariprazine's effectiveness on reducing BP-I mania events.
Short Description: Based on data from a large real-world claims database, patients with bipolar I disorder (BP-I) treated with cariprazine had significantly lower overall rates of manic events during follow-up than patients treated with either quetiapine or lurasidone. The rates of manic events occurring in the inpatient and outpatient settings were significantly lower in patients with BP-I after initiating cariprazine than either quetiapine or lurasidone (but not the emergency room).
Name of Sponsoring Organization(s): AbbVie, Inc.
Methods: This retrospective observational study used IQVIA PharMetrics® Plus database claims data (September 20142022) and included adults with BP-I and ≥2 claims for cariprazine, quetiapine, or lurasidone. Baseline period was 12 months preceding index (first claim). Follow-up period (≥3 months) spanned index date to earliest of: discontinuation(index AA), exposure to different AA or long-acting injectable antipsychotic, schizophrenia diagnosis, or data end. Manic events per patient-year(PPY) were compared and rate ratios calculated for cariprazine vs comparator AA.
Results: For manic events, cariprazine (n=4,125) versus quetiapine (n=12,177) baseline characteristics were well-balanced; mean age (39.1 vs 39.3 years), sex (64.9% vs 63.2% female); same for cariprazine(n=4,440) versus lurasidone(n=8,134); mean age (38.9 vs 38.8 years), sex (70.3% vs 70.4% female). Cariprazine patients had fewer manic events PPY than quetiapine (RR [95% CI]=0.57[0.44, 0.74], P.001), driven by fewer inpatient(IP)- (RR=0.49[0.30, 0.73], P.001) and outpatient (OP)-defined events (RR=0.57[0.43,0.75], P.001). Cariprazine had fewer manic events PPY than lurasidone (RR=0.71 [0.55, 0.93], P.05), due to fewer IP-defined (RR=0.64[0.45, 0.87], P 01) and OP-defined events (RR=0.71[0.53, 0.96], P.05). ER manic events were not significantly different between AAs.
Conclusions: Cariprazine-treated patients had fewer overall, IP, and OP manic events versus quetiapine or lurasidone, providing real-world evidence of cariprazine's effectiveness on reducing BP-I mania events.
Short Description: Based on data from a large real-world claims database, patients with bipolar I disorder (BP-I) treated with cariprazine had significantly lower overall rates of manic events during follow-up than patients treated with either quetiapine or lurasidone. The rates of manic events occurring in the inpatient and outpatient settings were significantly lower in patients with BP-I after initiating cariprazine than either quetiapine or lurasidone (but not the emergency room).
Name of Sponsoring Organization(s): AbbVie, Inc.
